Trials / Completed
CompletedNCT00986479
This is a Study to Determine the Antidepressant Effects of AZD6765
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6765 | Single IV infusion of 150 mg AZD6765. |
| DRUG | Placebo to AZD6765 | Single IV infusion of Placebo to AZD6765 |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-09-30
- Last updated
- 2014-10-21
- Results posted
- 2014-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00986479. Inclusion in this directory is not an endorsement.